ArticleRSC advances2026
Synthesis and characterization of bevacizumab-functionalized nanoliposomes loaded with regorafenib and fluorescent carbon dots for triple-negative breast cancer theranostics.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel theranostic nanoplatform was developed by a facile and green approach for targeted drug delivery and high-quality fluorescence imaging of triple-negative breast cancer cells (TNBCs). Innovatively synthesized fluorescent carbon dots (CDs) obtained by a hydrothermal method with a zeta potential of -18.4 mV had uniform sizes of <20 nm and high fluorescence quantum yield of 27.3% at 460 nm. Nanoliposomes (NLPs) were synthesized by a thin-film hydration method and loaded with CDs and regorafenib (CR-NLPs) and covalently functionalized with the bevacizumab antibody (BCR-NLPs) by the EDC-NHS method. Monodispersed and high colloidal BCR-NLPs showed a semi-spherical shape in the size range of 100-200 nm and zeta potential of -44.3 mV. HPLC of regorafenib revealed a maximum loading efficiency of 82% and sustained release of 96.4% during 120 h with the first-order kinetic model. The
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.